Shineco moves into point-of-care testing, inks stock purchase agreement with Chinese biotech

Business Handshake Man Social

Beijing-based Shineco announced on Tuesday that it has entered a stock purchase agreement through its subsidiary Shineco Life Science to acquire 51% of the issued equity interest of Changzhou Biowin Pharmaceutical (CBP), a Chinese biotechnology company with a focus on in-vitro diagnostic product research and development and biomedical products manufacturing.

The total amount of the transaction is greater than $10 million, to be paid in cash and with CBP's common stock.

This purchase is an initiative in Shineco’s strategy of moving into the point-of-care testing industry.

Shineco manufactures and distributes Chinese herbal medicines, organic agricultural produce, and specialized textiles, with a focus on biotechnology production.

In recent years, CBP has developed 55 rapid-diagnostic products in 16 categories, including cardiovascular diseases, infectious diseases, diabetes, and digestive diseases. Its COVID-19 and monkeypox virus detection reagents are registered in the EU and it is applying for an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA), Shineco said.



Page 1 of 15
Next Page